Veracyte VCYT Biopharmaceutical revenue — Total Revenue

Other product segments

Similar metrics at other companies

IBRXOther revenues — Total Revenue

$39K+388%

PTH

PTHSNet product revenues — Total Revenue

$10.67M—

LPR

LPROChange in estimated revenues — Total Revenue

-$702K+26.0%

PTH

PTHSLicense and collaboration revenues — Total Revenue

$241K—

LTHTotal center revenue — Total Revenue

$837.4M+13.8%

IRMDTotal devices revenue — Total Revenue

$15.39M+18.7%

FAQ

What is Veracyte's biopharmaceutical revenue — total revenue?

Veracyte (VCYT) reported biopharmaceutical revenue — total revenue of $301K in Q1 2026.

How has Veracyte's biopharmaceutical revenue — total revenue changed year-over-year?

Veracyte's biopharmaceutical revenue — total revenue decreased by 86.9% year-over-year, from $2.3M to $301K.

What is the long-term trend for Veracyte's biopharmaceutical revenue — total revenue?

Over 4 years (2021 to 2025), Veracyte's biopharmaceutical revenue — total revenue has grown at a -15.2% compound annual growth rate (CAGR), from $12.61M to $6.54M.

What does biopharmaceutical revenue — total revenue mean?

This metric represents the total revenue generated from services and collaborations provided to biopharmaceutical partners, such as clinical trial support or companion diagnostic development. It reflects the company's ability to monetize its proprietary diagnostic platforms through B2B partnerships rather than direct clinical testing. Tracking this revenue stream helps investors assess the company's diversification beyond core clinical diagnostic volumes and its integration into the broader drug development ecosystem.